MREO News and Press, Mereo BioPharma Group From 06/17/22

Update 7:55am: Adds Times report on advisers for a potential deal. The ADRs of Mereo BioPharma (MREO) jumped ~15% in the pre-market Friday after The Times reported that the Anglo-Dutch pharma giant AstraZeneca (NASDAQ:AZN) is considering a bid for the U.K.-based biotech. In 201...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com We’re entering the final day of trading for the week with a look at the biggest pre-market stock movers for Friday! Moving stocks this morning is delisting news, insider buyi...

The ADRs of Mereo BioPharma (MREO) jumped ~15% in the pre-market Monday after The Times reported that Anglo Dutch pharma giant AstraZeneca (NASDAQ:AZN) is considering a bid for the U.K.-based biotech. AstraZeneca (AZN) already has a partnership with Mereo (MREO). According to the re...

Needham analyst Chad Messer lowered the firm's price target on Mereo BioPharma (MREO -3.2%) to $5 from $10 after the co. reported "incremental" progress for Etigilimab at ASCO but keeps a Buy rating on the shares. The recent negative readouts from Roche's tiragolumab studies pressured the ent...

--ACTIVATE includes 2 Complete Responses, 4 Partial Responses and 10 patients with Stable Disease as of April 2022 data cut off-- --Etigilimab safe and well tolerated, no new safety signals-- --Prioritization initiatives extend cash runway to late 2024-- LONDON and...

Mereo BioPharma (NASDAQ:MREO) said on Thursday it had received a letter from the Nasdaq Stock Market that its American Depositary Shares had failed to maintain a minimum bid price of $1 over the previous 30 consecutive business days as required by the Listing Rules of Nasdaq.  The n...

Phase 1b/2 Study of Etigilimab and Nivolumab in Subjects with Select Locally Advanced or Metastatic Solid Tumors (ACTIVATE) 1 Complete Response (CR), 2 Partial Responses (PR) and 9 cases of Stable Diseases (SD) as of the February 10, 2022 abstract deadline Additional dat...

LONDON and REDWOOD CITY, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that on May 23, 2022, it rece...

If there’s one strategy growing in popularity right now, it’s “follow” the money. Whether you’re looking for penny stocks to buy or which stocks to invest in, “smart money” is a focus for many. Most companies won’t come out to state wh...

LONDON and REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Dr. Abdul M...